

4 March 2024

Breast Cancer Systemic Anti-cancer Therapies

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- **Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole): <5**
- **Abemaciclib + Fulvestrant: 7**
- **Alpelisib + Fulvestrant: <5**
- **Anthracycline (e.g. doxorubicin or epirubicin) as a single agent: <5**
- **Atezolizumab +Nab-paclitaxel/Paclitaxel: <5**
- **Capecitabine as a single agent: 17**
- **Eribulin as a single agent or in combination: <5**
- **Everolimus + Exemestane: <5**
- **Fulvestrant as a single agent: 15**
- **Lapatinib: <5**
- **Neratinib: <5**
- **Parp Inhibitors (Olaparib/Talazoparib): <5** **Olaparib +EAP: <5**
- **Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole): <5**
- **Palbociclib + Fulvestrant: 9** **Palbociclib SA: 37**
- **Pembrolizumab: <5**
- **Platinum (e.g. carboplatin or cisplatin) as a single agent: <5**
- **Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole): <5**
- **Ribociclib + Fulvestrant: <5** **Ribociclib SA: 16**
- **Sacituzumab Govitecan: <5**
- **Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent. Paclitaxel: 10, Nab-paclitaxel: <5**
- **Taxane and/or Anthracycline in combination: <5**
- **Trastuzumab as a single agent or in combination: 16**
- **Trastuzumab emtansine: 10**
- **Transtuzumab deruxtecan: <5**
- **Any other active systemic anti-cancer therapy:**
 - **AC: <5**
 - **D-Carbo Phesgo: <5**
 - **Docetaxel+Cyclophosphamide: <5**
 - **D-Phesgo: 9**
 - **EC 50: <5**
 - **EC D Herceptin: 6**

4 March 2024

- EC D: 24
- EC D Phesgo: 13
- EC PC: 15
- EC Wky Paclitaxel Phesgo: 9
- FEC 50: <5
- FEC D Phesgo: 6
- Goserelin: 7
- Paclitaxel wky Herceptin: 16
- Paclitaxel Wky Phesgo: <5
- Vinerolbine: <5
- Zolendronic Acit: 13
- Tucatinib Capecitabine Trastuzumab: <5

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Breast Cancer Trial/Study Activity 1 March 2024			
OPTIMA	Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis	47	Open
SMALL	A Phase III, randomised, multi-centre trial addressing overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision	32	Open
POETIC-A	PreOperative Endocrine Therapy for Individualised Care with Abemaciclib	8	Open
EndoNET	Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine treatment in post-menopausal women	<5	Open
ATNEC	Axillary management in T1-3N1M0 breast cancer patients with FNA or core biopsy proven nodal metastases at	<5	Open

4 March 2024

	presentation who convert to node negative after NEoadjuvant Chemotherapy		
HER2-Radicals	The HER2-RADiCAL study (Response ADaptive CAre pLan) – Tailoring treatment for HER2 positive early breast cancer	<5	Open

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.